Paclitaxel bụ otu n'ime ọgwụ chemotherapy nke ọgbọ atọ a ma ama, mana mmiri mmiri ya adịghị mma, ọ dịkwa mkpa ka agbaze ya na ihe mgbaze organic. naanị na-ezere mmeghachi omume hypersensitivity / toxicity nke ihe ndị na-edozi ahụ na-akpata, ma ọ dịghị achọ ọgwụgwọ hormone; Ọ nwekwara ike ime ka albumin na-ebu paclitaxel na-ekesa n'ọbara ngwa ngwa, na-agafe mkpụrụ ndụ endothelial site na endocytosis nke onye na-anabata ya, ma na-emewanyewanye ụbụrụ ụbụrụ. site na elu permeability na njigide mmetụta (EPR mmetụta) nke etuto ahụ, nke na-aga n'ihu na-egosi pharmacokinetic uru.
N'oge nke immunotherapy, ịdị irè nke otu ọgwụ ezughị, na ebumnobi remission ọnụego (ORR) nke otu ọgwụ adịghị agafe 20%; Otu esi gbasaa ndị na-erite uru nke immunotherapy, ngwakọta ọgwụgwọ nwere ike ịbụ ihe ngwọta dị irè, n'ime ya. Usoro ọgwụgwọ chemotherapy jikọtara ọnụ bụ ebe dị ọkụ nke nyocha ugbu a.
Site na nke a, albumin-bound paclitaxel nwere uru nke ya, ORR ya dị elu, ọ nwere ike igbu mkpụrụ ndụ tumor nke ọma, ma kwalite ikpughe nke antigen tumor; Ọ dịghị ọgwụgwọ hormone dị mkpa iji zere immunosuppression; Ịba ụba anụ ahụ dị elu na-ebelata mmebi. nkịtị anụ ahụ.
Mara: Enwere ike ịrụ ọrụ yana ngwa ewepụtara n'isiokwu a niile sitere na akwụkwọ ebipụtara.
Yunnan Hande Biotechnology Co., Ltd e ọkachamara na mmepụta nkepaclitaxel APIn'ihi na ihe karịrị 20 afọ, na bụ otu n'ime ụwa kwụụrụ onwe emepụta nke paclitaxel API, a osisi-enwetara mgbochi ọrịa cancer ọgwụ, nke US FDA kwadoro, European EDQM, Australian TGA, Chinese CFDA, India, Japan na ndị ọzọ mba regulatory ụlọ ọrụ. .Hande nwere ike inye ọ bụghị naanị dị elupaclitaxel akụrụngwa,ma ọ bụkwa ọrụ nkwalite teknụzụ metụtara usoro paclitaxel. Maka ozi ndị ọzọ, biko nweere onwe gị ịkpọtụrụ anyị na 18187887160.
Oge nzipu: Dec-29-2022